{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:36:42Z","timestamp":1792082202052,"version":"4.4.0"},"reference-count":189,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1517\/14728214.13.3.479","type":"journal-article","created":{"date-parts":[[2008,9,2]],"date-time":"2008-09-02T12:33:56Z","timestamp":1220358836000},"page":"479-495","source":"Crossref","is-referenced-by-count":43,"title":["Emerging drugs for schizophrenia"],"prefix":"10.1517","volume":"13","author":[{"given":"Ofer","family":"Agid","sequence":"first","affiliation":[{"name":"University of Toronto, Centre for Addiction and Mental Health (CAMH), Schizophrenia Program, Department of Psychiatry, 250 College Street, Toronto, Ontario M5T 1R8, Canada ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shitij","family":"Kapur","sequence":"additional","affiliation":[{"name":"King's College, Institute of Psychiatry, Section of Schizophrenia, Imaging and Therapeutics, Department of Psychological Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[{"name":"University of Toronto, Centre for Addiction and Mental Health (CAMH), Medication Assessment Program for Schizophrenia (MAPS) Clinic, Faculty of Medicine, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2008,9,2]]},"reference":[{"key":"e_1_3_1_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035458"},{"key":"e_1_3_1_2_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001270050180"},{"key":"e_1_3_1_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340109"},{"key":"e_1_3_1_2_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674379504007s06"},{"key":"e_1_3_1_2_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.135.2.164"},{"key":"e_1_3_1_2_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1145194"},{"key":"e_1_3_1_2_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.11.1550"},{"key":"e_1_3_1_2_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.11.1474"},{"key":"e_1_3_1_2_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853899608999120"},{"key":"e_1_3_1_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/6.1.70"},{"key":"e_1_3_1_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.08.005"},{"key":"e_1_3_1_2_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.3.321"},{"key":"e_1_3_1_2_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20823"},{"key":"e_1_3_1_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)90206-8"},{"key":"e_1_3_1_2_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_3_1_2_17_1","author":"Tuunainen","year":"2000","unstructured":"Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;(2):CD000966","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_2_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401230309085668"},{"key":"e_1_3_1_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01251-3"},{"key":"e_1_3_1_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.010"},{"key":"e_1_3_1_2_21_1","first-page":"390","volume":"25","author":"Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25(3):390-2","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_1_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)20710-8"},{"key":"e_1_3_1_2_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(200004)15:3<179::AID-HUP156>3.0.CO;2-N"},{"key":"e_1_3_1_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1999.tb05933.x"},{"key":"e_1_3_1_2_25_1","first-page":"47","volume":"55","author":"Meltzer","year":"1994","unstructured":"Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(Suppl B):47-52","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_2_26_1","first-page":"275","volume":"28","author":"Remington","year":"2003","unstructured":"Remington G. Understanding antipsychotic \u201catypicality\u201d: a clinical and pharmacological moving target. J Psychiatry Neurosci 2003;28(4):275-84","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_3_1_2_27_1","first-page":"161","volume":"25","author":"Kapur","year":"2000","unstructured":"Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25(2):161-6","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_3_1_2_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.360"},{"key":"e_1_3_1_2_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700106"},{"key":"e_1_3_1_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4000336"},{"key":"e_1_3_1_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63079-6"},{"key":"e_1_3_1_2_32_1","first-page":"109","volume":"44","author":"Grunder","year":"2003","unstructured":"Grunder G, Siessmeier T, Piel M, et al. Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. J Nucl Med 2003;44(1):109-16","journal-title":"J Nucl Med"},{"key":"e_1_3_1_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2004.02.002"},{"key":"e_1_3_1_2_34_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.157.1.41"},{"key":"e_1_3_1_2_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2006.00887.x"},{"key":"e_1_3_1_2_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.3.249"},{"key":"e_1_3_1_2_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1987.01800190080012"},{"key":"e_1_3_1_2_38_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004110"},{"key":"e_1_3_1_2_39_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002"},{"key":"e_1_3_1_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-6163.2002.tb01566.x"},{"key":"e_1_3_1_2_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-007-0182-6"},{"key":"e_1_3_1_2_42_1","doi-asserted-by":"publisher","DOI":"10.2152\/jmi.52.284"},{"key":"e_1_3_1_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00099-2"},{"key":"e_1_3_1_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01256-2"},{"key":"e_1_3_1_2_45_1","first-page":"5","author":"Kane","year":"2003","unstructured":"Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(Suppl 12):5-19","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_2_46_1","first-page":"3","author":"McEvoy","year":"1999","unstructured":"McEvoy J, Scheifler P, Frances A. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 1999;60(Suppl 11):3-80","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_2_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401230591002084"},{"key":"e_1_3_1_2_48_1","unstructured":"IMS H. Atypical antipsychotics - generating evidence to inform policy and practice. Pharmaceutical Information Leading Products by Global Pharmaceutical Sales 2005. Available from: http:\/\/research.imshealth.com\/research\/research_schizophrenia.htm"},{"key":"e_1_3_1_2_49_1","unstructured":"Stagnitti MN. MEPS: Characteristics and Prescribed Medicines Files. Agency for Healthcare Research and Quality Household Component of the Medical Expenditure Panel Survey (MEPS-HC) U.S. Department of Health & Human Services. Available from: http:\/\/meps.ahrq.gov\/mepsweb\/data_fi les\/publications\/st144\/stat144.pdf."},{"key":"e_1_3_1_2_50_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2006.57.12.1693"},{"key":"e_1_3_1_2_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200307000-00006"},{"key":"e_1_3_1_2_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.10.1079"},{"key":"e_1_3_1_2_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"e_1_3_1_2_54_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1209"},{"key":"e_1_3_1_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"e_1_3_1_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13306-5"},{"key":"e_1_3_1_2_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.20.2693"},{"key":"e_1_3_1_2_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7273.1371"},{"key":"e_1_3_1_2_59_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200822070-00002"},{"key":"e_1_3_1_2_60_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.6.537"},{"key":"e_1_3_1_2_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbi004"},{"key":"e_1_3_1_2_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890010203"},{"key":"e_1_3_1_2_63_1","first-page":"109","volume":"7","author":"Hyttel","year":"1989","unstructured":"Hyttel J, Arnt J, van den Berghe M. Selective dopamine D1 and D2 receptor antagonists. Psychopharmacol Ser 1989;7:109-22","journal-title":"Psychopharmacol Ser"},{"key":"e_1_3_1_2_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246069"},{"key":"e_1_3_1_2_65_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.9.1620"},{"key":"e_1_3_1_2_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246070"},{"key":"e_1_3_1_2_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246071"},{"key":"e_1_3_1_2_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1999.tb01482.x"},{"key":"e_1_3_1_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(99)00045-4"},{"key":"e_1_3_1_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/385634a0"},{"key":"e_1_3_1_2_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5460.2020"},{"key":"e_1_3_1_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.011"},{"key":"e_1_3_1_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.03.033"},{"key":"e_1_3_1_2_74_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-23-08677.2000"},{"key":"e_1_3_1_2_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830150047009"},{"key":"e_1_3_1_2_76_1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S0022-3565(24)39184-0","volume":"294","author":"Reavill","year":"2000","unstructured":"Reavill C, Taylor SG, Wood MD, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000;294(3):1154-65","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.02.051"},{"key":"e_1_3_1_2_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300114"},{"key":"e_1_3_1_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03491-4"},{"key":"e_1_3_1_2_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050091"},{"key":"e_1_3_1_2_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/350610a0"},{"key":"e_1_3_1_2_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180085011"},{"key":"e_1_3_1_2_83_1","author":"Shahid","year":"2008","unstructured":"Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologicagent with a unique human receptor signature. J Psychopharmacol 2008","journal-title":"J Psychopharmacol"},{"key":"e_1_3_1_2_84_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"e_1_3_1_2_85_1","first-page":"539","volume":"8","author":"Newman-Tancredi","year":"2007","unstructured":"Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8(7):539-54","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_1_2_86_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106073126"},{"key":"e_1_3_1_2_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-006-9062-8"},{"key":"e_1_3_1_2_88_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","volume":"25","author":"Lahti","year":"2001","unstructured":"Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001;25(4):455-67","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_1_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(99)00029-1"},{"key":"e_1_3_1_2_90_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.10.1301"},{"key":"e_1_3_1_2_91_1","first-page":"29","author":"Tamminga","year":"1995","unstructured":"Tamminga CA, Holcomb HH, Gao XM, et al. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 1995;10(Suppl 3):29-37","journal-title":"Int Clin Psychopharmacol"},{"key":"e_1_3_1_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00423-9"},{"key":"e_1_3_1_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.017"},{"key":"e_1_3_1_2_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1632"},{"key":"e_1_3_1_2_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.1.21"},{"key":"e_1_3_1_2_96_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.1.29"},{"key":"e_1_3_1_2_97_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.9.1367"},{"key":"e_1_3_1_2_98_1","author":"Tuominen","year":"2006","unstructured":"Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006;(2):CD003730","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_2_99_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.06081358"},{"key":"e_1_3_1_2_100_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0002432"},{"key":"e_1_3_1_2_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1997.tb01489.x"},{"key":"e_1_3_1_2_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90021-3"},{"key":"e_1_3_1_2_103_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039735"},{"key":"e_1_3_1_2_104_1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0022-3565(24)38151-0","volume":"289","author":"Hu","year":"1999","unstructured":"Hu G, Duffy P, Swanson C, et al. The regulation of dopamine transmission by metabotropic glutamate receptors. J Pharmacol Exp Ther 1999;289(1):412-6","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_2_105_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","volume":"291","author":"Cartmell","year":"1999","unstructured":"Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 1999;291(1):161-70","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_2_106_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.110809"},{"key":"e_1_3_1_2_107_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","volume":"299","author":"Schoepp","year":"2001","unstructured":"Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001;299(1):12-20","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_2_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0907-1018"},{"key":"e_1_3_1_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.11.007"},{"key":"e_1_3_1_2_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.06.029"},{"key":"e_1_3_1_2_111_1","author":"Premkumar","year":"2006","unstructured":"Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst Rev 2006;(4):CD005962","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_2_112_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997"},{"key":"e_1_3_1_2_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90288-F"},{"key":"e_1_3_1_2_114_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-07-02748.1998"},{"key":"e_1_3_1_2_115_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-07-02740.1998"},{"key":"e_1_3_1_2_116_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620030-00001"},{"key":"e_1_3_1_2_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2006.05.006"},{"key":"e_1_3_1_2_118_1","author":"Goff","year":"2007","unstructured":"Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2007","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_1_2_119_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07050724"},{"key":"e_1_3_1_2_120_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST0340055"},{"key":"e_1_3_1_2_121_1","author":"Shim","year":"2007","unstructured":"Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2007","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"e_1_3_1_2_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.09.012"},{"key":"e_1_3_1_2_123_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.11.1196"},{"key":"e_1_3_1_2_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2003.09.010"},{"key":"e_1_3_1_2_125_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","volume":"299","author":"Weiner","year":"2001","unstructured":"Weiner DM, Burstein ES, Nash N, et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001;299(1):268-76","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_2_126_1","unstructured":"ACADIA and A. Pharmaceuticals. Pimavanserin 2007. Available from: http:\/\/www.acadia-pharm.com\/"},{"key":"e_1_3_1_2_127_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500108"},{"key":"e_1_3_1_2_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.05.001"},{"key":"e_1_3_1_2_129_1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-3565(25)38596-4","volume":"268","author":"Roth","year":"1994","unstructured":"Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268(3):1403-10","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_2_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1683-8"},{"key":"e_1_3_1_2_131_1","unstructured":"Goldman-Rakic P. Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory in psychopathology and the brain. In: Carroll B Barrett J editors. Raven Press: New York; 1991. p. 1-23"},{"key":"e_1_3_1_2_132_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.10-07-02125.1990"},{"key":"e_1_3_1_2_133_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2999977"},{"key":"e_1_3_1_2_134_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.08-11-04287.1988"},{"key":"e_1_3_1_2_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1794-x"},{"key":"e_1_3_1_2_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00249-4"},{"key":"e_1_3_1_2_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(00)00199-6"},{"key":"e_1_3_1_2_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1750-1"},{"key":"e_1_3_1_2_139_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a033320"},{"key":"e_1_3_1_2_140_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125004060"},{"key":"e_1_3_1_2_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2003.12.023"},{"key":"e_1_3_1_2_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(95)00028-5"},{"key":"e_1_3_1_2_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(06)78008-4"},{"key":"e_1_3_1_2_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.07.015"},{"key":"e_1_3_1_2_145_1","author":"Dyer","year":"2008","unstructured":"Dyer MA, Freudenreich O, Culhane MA, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008","journal-title":"Schizophr Res"},{"key":"e_1_3_1_2_146_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280117feb"},{"key":"e_1_3_1_2_147_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0675-x"},{"key":"e_1_3_1_2_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001416"},{"key":"e_1_3_1_2_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.11.003"},{"key":"e_1_3_1_2_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.01.017"},{"key":"e_1_3_1_2_151_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001199"},{"key":"e_1_3_1_2_152_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn992"},{"key":"e_1_3_1_2_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00287-X"},{"key":"e_1_3_1_2_154_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566524033479654"},{"key":"e_1_3_1_2_155_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550160091022"},{"key":"e_1_3_1_2_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6865(99)00027-8"},{"key":"e_1_3_1_2_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(97)00038-5"},{"key":"e_1_3_1_2_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.05.004"},{"key":"e_1_3_1_2_159_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31812eed10"},{"key":"e_1_3_1_2_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(03)45003-6"},{"key":"e_1_3_1_2_161_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-006-6027-5"},{"key":"e_1_3_1_2_162_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199906030-00008"},{"key":"e_1_3_1_2_163_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-007-0660-5"},{"key":"e_1_3_1_2_164_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00221-006-0503-x"},{"key":"e_1_3_1_2_165_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.178.2.116"},{"key":"e_1_3_1_2_166_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.164.5.679"},{"key":"e_1_3_1_2_167_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1989.tb00576.x"},{"key":"e_1_3_1_2_168_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200509000-00014"},{"key":"e_1_3_1_2_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2006.08.006"},{"key":"e_1_3_1_2_170_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050987"},{"key":"e_1_3_1_2_171_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.975"},{"key":"e_1_3_1_2_172_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1905"},{"key":"e_1_3_1_2_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(94)00292-U"},{"key":"e_1_3_1_2_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0143-4179(98)90075-0"},{"key":"e_1_3_1_2_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2006.06.004"},{"key":"e_1_3_1_2_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(99)00062-0"},{"key":"e_1_3_1_2_177_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161208784480243"},{"key":"e_1_3_1_2_178_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03033242"},{"key":"e_1_3_1_2_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2008.01.013"},{"key":"e_1_3_1_2_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.11.016"},{"key":"e_1_3_1_2_181_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yco.0000214338.29378.29"},{"key":"e_1_3_1_2_182_1","unstructured":"NIH and N.I.o. Health. ClinicalTrials.gov 2007. Available from: http:\/\/clinicaltrials.gov"},{"key":"e_1_3_1_2_183_1","unstructured":"SRF and S.R. Forum Drugs in Clinical Trials for Schizophrenia; 2007"},{"key":"e_1_3_1_2_184_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbi039"},{"key":"e_1_3_1_2_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.004"},{"key":"e_1_3_1_2_186_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001556"},{"key":"e_1_3_1_2_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(03)00248-8"},{"key":"e_1_3_1_2_188_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02221-2"},{"key":"e_1_3_1_2_189_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.yco.0000214341.52249.59"},{"key":"e_1_3_1_2_190_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002009"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14728214.13.3.479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:58:54Z","timestamp":1744282734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14728214.13.3.479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":189,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1517\/14728214.13.3.479"],"URL":"https:\/\/doi.org\/10.1517\/14728214.13.3.479","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}